IDEC-C2B8 Antibody Is in Phase III Testing for B-Cell Lymphoma
SAN DIEGO, Calif--IDEC Pharmaceuticals Corporation has begun a phase III trial of its anti-lymphoma antibody IDEC-C2B8 in patients with relapsed low-grade and follicular non-Hodgkin's lymphomas. The company is developing the agent in collaboration with Genentech, Inc.
SAN DIEGO, Calif--IDEC Pharmaceuticals Corporation has begun aphase III trial of its anti-lymphoma antibody IDEC-C2B8 in patientswith relapsed low-grade and follicular non-Hodgkin's lymphomas.The company is developing the agent in collaboration with Genentech,Inc.
Up to 200 patients in this single-arm, single-agent trial willreceive four weekly infusions of IDEC-C2B8.
The antibody binds to the CD20 antigen, which is expressed onthe surface of mature B cells and B-cell tumors, but not on B-cellprecursors or plasma cells. Host defenses are thus recruited tokill both malignant and normal B cells. After treatment, the normalB cells regenerate from stem cells within months,IDEC said.
Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care
Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.
